Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography
Abstract Background Few challenges are faced with the introduction of anti-VEGF agents as a modality of treatment for retinopathy of prematurity. The clinical behavior and time course of regression post injection differ compared to post laser ablation. This study aims to evaluate the long-term perip...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-08-01
|
| Series: | International Journal of Retina and Vitreous |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40942-022-00402-3 |
| _version_ | 1811342845813981184 |
|---|---|
| author | Raghad Al Rasheed Mohammad Idrees Adhi Sarah Abdullah Alowedi Bayan Albdah Tariq Aldebasi Mohammad A. Hazzazi |
| author_facet | Raghad Al Rasheed Mohammad Idrees Adhi Sarah Abdullah Alowedi Bayan Albdah Tariq Aldebasi Mohammad A. Hazzazi |
| author_sort | Raghad Al Rasheed |
| collection | DOAJ |
| description | Abstract Background Few challenges are faced with the introduction of anti-VEGF agents as a modality of treatment for retinopathy of prematurity. The clinical behavior and time course of regression post injection differ compared to post laser ablation. This study aims to evaluate the long-term peripheral retinal vascularization outcome of Ranibizumab intravitreal injections monotherapy in the treatment of retinopathy of prematurity. Method Hospital-based quasi-experimental study. Include ROP patients who received intravitreal ranibizumab (IVR), as primary treatment for type 1 ROP. Patients were examined under general anaesthesia to ensure documentation of all junctions of vascular and avascular zones. Images were taken by RetCam III, Phoenix ICON and fluorescein angiography was performed to describe vascular behaviors. Results The mean gestational age was 24.67 weeks and the mean postmenstrual age at the time of intravitreal ranibizumab treatment was 36.3 weeks. Fluorescein angiography was performed at 155–288 weeks; most eyes showed two disk diameters of avascular peripheral retina. Only eyes with original aggressive ROP who required a second injection (six eyes) showed extensive peripheral avascular retina reaching zone I (13.64%). Neovascularization was evident in five eyes (11.36%), all with an original aggressive ROP and received multiple injections. Conclusions Ranibizumab treated babies with incomplete retinal vascularization require close and long-term follow-up visits to assess post injection vascular behavior. Peripheral retinal avascular zone of more than two-disc diameters was present in most of the patients evidenced by fluorescein angiography. Babies with initial diagnosis of aggressive ROP are more likely to have persistent peripheral neovascularization. |
| first_indexed | 2024-04-13T19:19:14Z |
| format | Article |
| id | doaj.art-8a3247ed26804888890f494284bbb81b |
| institution | Directory Open Access Journal |
| issn | 2056-9920 |
| language | English |
| last_indexed | 2024-04-13T19:19:14Z |
| publishDate | 2022-08-01 |
| publisher | BMC |
| record_format | Article |
| series | International Journal of Retina and Vitreous |
| spelling | doaj.art-8a3247ed26804888890f494284bbb81b2022-12-22T02:33:36ZengBMCInternational Journal of Retina and Vitreous2056-99202022-08-01811810.1186/s40942-022-00402-3Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiographyRaghad Al Rasheed0Mohammad Idrees Adhi1Sarah Abdullah Alowedi2Bayan Albdah3Tariq Aldebasi4Mohammad A. Hazzazi5Department of Ophthalmology, King Abdulaziz Medical City, National Guard Health AffairsDepartment of Ophthalmology, King Abdulaziz Medical City, National Guard Health AffairsDepartment of Ophthalmology, King Abdulaziz Medical City, National Guard Health AffairsKing Abdullah International Medical Research CenterDepartment of Ophthalmology, King Abdulaziz Medical City, National Guard Health AffairsDepartment of Ophthalmology, King Abdulaziz Medical City, National Guard Health AffairsAbstract Background Few challenges are faced with the introduction of anti-VEGF agents as a modality of treatment for retinopathy of prematurity. The clinical behavior and time course of regression post injection differ compared to post laser ablation. This study aims to evaluate the long-term peripheral retinal vascularization outcome of Ranibizumab intravitreal injections monotherapy in the treatment of retinopathy of prematurity. Method Hospital-based quasi-experimental study. Include ROP patients who received intravitreal ranibizumab (IVR), as primary treatment for type 1 ROP. Patients were examined under general anaesthesia to ensure documentation of all junctions of vascular and avascular zones. Images were taken by RetCam III, Phoenix ICON and fluorescein angiography was performed to describe vascular behaviors. Results The mean gestational age was 24.67 weeks and the mean postmenstrual age at the time of intravitreal ranibizumab treatment was 36.3 weeks. Fluorescein angiography was performed at 155–288 weeks; most eyes showed two disk diameters of avascular peripheral retina. Only eyes with original aggressive ROP who required a second injection (six eyes) showed extensive peripheral avascular retina reaching zone I (13.64%). Neovascularization was evident in five eyes (11.36%), all with an original aggressive ROP and received multiple injections. Conclusions Ranibizumab treated babies with incomplete retinal vascularization require close and long-term follow-up visits to assess post injection vascular behavior. Peripheral retinal avascular zone of more than two-disc diameters was present in most of the patients evidenced by fluorescein angiography. Babies with initial diagnosis of aggressive ROP are more likely to have persistent peripheral neovascularization.https://doi.org/10.1186/s40942-022-00402-3Anti- VEGFFluorescein AngiographyPeripheral retinal vascularizationRanibizumabRetinopathy of PrematurityRetCam |
| spellingShingle | Raghad Al Rasheed Mohammad Idrees Adhi Sarah Abdullah Alowedi Bayan Albdah Tariq Aldebasi Mohammad A. Hazzazi Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography International Journal of Retina and Vitreous Anti- VEGF Fluorescein Angiography Peripheral retinal vascularization Ranibizumab Retinopathy of Prematurity RetCam |
| title | Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography |
| title_full | Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography |
| title_fullStr | Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography |
| title_full_unstemmed | Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography |
| title_short | Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography |
| title_sort | long term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography |
| topic | Anti- VEGF Fluorescein Angiography Peripheral retinal vascularization Ranibizumab Retinopathy of Prematurity RetCam |
| url | https://doi.org/10.1186/s40942-022-00402-3 |
| work_keys_str_mv | AT raghadalrasheed longtermperipheralretinalvascularbehaviorinretinopathyofprematuritypatientstreatedwithranibizumabintravitrealinjectionasmonotherapyusingfluoresceinangiography AT mohammadidreesadhi longtermperipheralretinalvascularbehaviorinretinopathyofprematuritypatientstreatedwithranibizumabintravitrealinjectionasmonotherapyusingfluoresceinangiography AT sarahabdullahalowedi longtermperipheralretinalvascularbehaviorinretinopathyofprematuritypatientstreatedwithranibizumabintravitrealinjectionasmonotherapyusingfluoresceinangiography AT bayanalbdah longtermperipheralretinalvascularbehaviorinretinopathyofprematuritypatientstreatedwithranibizumabintravitrealinjectionasmonotherapyusingfluoresceinangiography AT tariqaldebasi longtermperipheralretinalvascularbehaviorinretinopathyofprematuritypatientstreatedwithranibizumabintravitrealinjectionasmonotherapyusingfluoresceinangiography AT mohammadahazzazi longtermperipheralretinalvascularbehaviorinretinopathyofprematuritypatientstreatedwithranibizumabintravitrealinjectionasmonotherapyusingfluoresceinangiography |